ImmunoCellular Therapeutics aspires to be an industry-leading, independent, immunotherapy company serving patients with cancer.
ImmunoCellular believes that the company’s proprietary cancer immunotherapy technology platform is broadly enabling, with the potential to generate many immunotherapeutic products that can improve cancer treatment and bring meaningful benefit to patients and their families
ImmunoCellular has optimized a proprietary manufacturing process for dendritic cell (DC) immunotherapeutics to accelerate the development and potential commercialization of the company’s portfolio: ICT-107, ICT-121 and ICT-140. ImmunoCellular is investing strategically to build the infrastructure and operational capabilities needed to manage a growing development portfolio.
The immuno-oncology field continues to be fertile ground for new anti-cancer approaches, many of which could be complementary to the company’s current DC cell-based efforts. ImmunoCellular’s DC platform has synergistic potential in combination with other immunotherapy approaches, including a range of T-cell based therapies, antibodies, checkpoint inhibitors and co-stimulatory technologies.
As ImmunoCellular’s clinical pipeline advances, strategic investments will position the company for long-term value creation and provide a foundation for further progress. An established platform, a multi-product pipeline including a late-stage asset, and a network of support from the global oncology community contribute to ImmunoCellular’s attractiveness as a potential partner.
ImmunoCellular welcomes inquiries from pharmaceutical and biotechnology companies, academic institutions, and other potential collaborators. For more information, please contact email@example.com